Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer
Autore:
Robertson, MJ; Cameron, C; Atkins, MB; Gordon, MS; Lotze, MT; Sherman, ML; Ritz, J;
Indirizzi:
Indiana Univ, Med Ctr, Div Hematol Oncol, Indianapolis, IN 46202 USA Indiana Univ Indianapolis IN USA 46202 Oncol, Indianapolis, IN 46202 USA Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA DanaFarber Canc Inst Boston MA USA 02115 ignancies, Boston, MA 02115 USA Tufts Univ, New England Med Ctr, Tupper Res Inst, Boston, MA 02111 USA Tufts Univ Boston MA USA 02111 Ctr, Tupper Res Inst, Boston, MA 02111 USA Tufts Univ, New England Med Ctr, Div Hematol Oncol, Boston, MA 02111 USA Tufts Univ Boston MA USA 02111 r, Div Hematol Oncol, Boston, MA 02111 USA Univ Pittsburgh, Sch Med, Pittsburgh Canc Inst, Div Surg Oncol, Pittsburgh, Univ Pittsburgh Pittsburgh PA USA 15261 Inst, Div Surg Oncol, Pittsburgh, Genet Inst, Cambridge, MA 02140 USA Genet Inst Cambridge MA USA 02140Genet Inst, Cambridge, MA 02140 USA
Titolo Testata:
CLINICAL CANCER RESEARCH
fascicolo: 1, volume: 5, anno: 1999,
pagine: 9 - 16
SICI:
1078-0432(199901)5:1<9:IEOI1A>2.0.ZU;2-3
Fonte:
ISI
Lingua:
ENG
Soggetto:
CELL STIMULATORY FACTOR; NATURAL-KILLER-CELL; INTERFERON-GAMMA PRODUCTION; VIRUS-INFECTED CELLS; VERSUS-HOST DISEASE; T-CELLS; NK-CELLS; ADHESION MOLECULES; CYTOLYTIC ACTIVITY; RECOMBINANT IL-12;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
55
Recensione:
Indirizzi per estratti:
Indirizzo: Robertson, MJ Indiananutiv, Sch Med, Dept Med, Bone Marrow Transplant Program, 1044 W Wal Indiana Univ 1044 W Walnut St,Room R4-202 Indianapolis IN USA 46202
Citazione:
M.J. Robertson et al., "Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer", CLIN CANC R, 5(1), 1999, pp. 9-16

Abstract

The immunological effects of recombinant human interleukin 12 (rhIL-12) administration were examined during the conduct of a Phase I clinical trial, Forty patients with advanced cancer received bolus i.v. injections of rhIL-12 in doses ranging between 3 and 1000 ng/kg, Dose-dependent increases in serum IFN-gamma levels were seen during rhIL-12 therapy. Significant lymphopenia was observed 24 h after single i.v. injections of rhIL-12 at each doselevel, The degree of lymphopenia was dose dependent, and a plateau effect was seen with rhIL-12 doses of 100 ng/kg and higher. Lymphocyte counts reached nadir levels at approximately 10 h after rhIL-12 injection and returnedto baseline within 14 days postinjection, Rebound lymphocytosis as seen after interleukin 2 therapy, was not observed after recovery from rhIL-12-induced lymphopenia. rhIL-12-induced lymphopenia involved all, major lymphocyte subsets, although natural killer (NK) cell numbers were the most profoundly affected, and CD4 T-cell numbers mere the least affected. CD2, LFA-1, and CD56 were transiently up-regulated on the surface of NK cells exposed to rhIL-12 in vivo. Peripheral blood mononuclear cells obtained from cancer patients before rhIL-12 therapy exhibited defective NK cell cytotoxicity and T-cell-proliferative responses. Peripheral blood mononuclear cells obtainedafter lymphocyte recovery following the administration of a single 500 ng/kg dose of rhIL-12 displayed augmented NK cell cytolytic activity in four of four patients tested and enhanced T-cell proliferation in three of four patients tested. These studies confirm that doses of rhIL-12 resulting in significant immunological activity can be administered with acceptable toxicity to cancer patients. Furthermore, rhIL-12 therapy can reverse defects in NK cell and T-cell function that are associated with advanced cancer in humans.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/11/20 alle ore 10:19:41